Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Brazil gets first active ingredients for AstraZeneca vaccine from China

Published 02/06/2021, 04:58 PM
Updated 02/06/2021, 05:00 PM
© Reuters. FILE PHOTO: Coronavirus disease vaccination in Rio de Janeiro

By Sergio Queiroz

RIO DE JANEIRO (Reuters) - A first shipment of 88 liters of active ingredients to make AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine in Brazil arrived from China on Saturday, essential input to speed the country's troubled vaccination program.

With those supplies flown into Rio de Janeiro on a cargo plane, the Fiocruz biomedical center can begin filling and finishing 2.8 million doses. The federally funded center expects to receive more ingredients this month to make a total of 15 million shots of the vaccine developed with Oxford University.

The Fiocruz production line, originally scheduled to start producing in December, has sat idle due to delays getting the first shipment of supplies from China.

The AstraZeneca Plc vaccine is the central pillar of Brazil's national inoculation program and the federal government has ordered material for Fiocruz to make up to 100 million shots.

To start inoculating its 210 million people, Brazil has relied initially on the Chinese vaccine developed by Sinovac Biotech Ltd and 2 million ready-to-use AstraZeneca shots imported from India last month.

Pfizer Inc (NYSE:PFE) applied on Friday for full regulatory approval in Brazil of its COVID-19 vaccine developed with BioNTech Se, the company said.

It is the second vaccine submitted for registration in Brazil. AstraZeneca applied on Jan. 29 for full regulatory approval of its vaccine.

President Jair Bolsonaro, who says he will not take any COVID-19 shot, is under pressure after a slow and patchy vaccine roll-out in Brazil, which now faces a second wave of infections.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Bolsonaro referred to the virus as a "little flu" but his government faces mounting criticism over its handling of the world's second-deadliest coronavirus outbreak that has killed more than 231,000 Brazilians.

Sao Paulo's Butantan biomedical institute said on Saturday it has begun to fill-and-finish 8.6 million doses of Sinovac's vaccine called Coronavac with ingredients that arrived from China on Wednesday.

Butantan said it expects to receive another supply of ingredients on Wednesday to make an additional 8.7 million doses.

Latest comments

first create virus ,than send vaccine , true business county
We will not win. The virus will continue to mutate effectively thwarting mankind's efforts to stop it.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.